In KitV558Δ/+ mouse GIST model, the combination of imatinib and CTLA-4 inhibitors enhanced the infiltration of CD8+ T cells evidently, strengthened the production of IFNγ markedly, and reduced the tumor size significantly [95]. This evidence concerns the gene CTLA4 and gastrointestinal stromal tumor.